

Oral Glucose Tablets versus Gel or Solution for the Treatment of Mild Hypoglycemia: Comparative Clinical Effectiveness

Service Line: Rapid Response Service

Version: 1.0

Publication Date: May 8, 2019 Report Length: 6 Pages



Authors: Ke Xin Li, Aleksandra Grobelna

Cite As: Oral glucose tablets versus gel or solution for the treatment of mild hypoglycemia: comparative clinical effectiveness. Ottawa: CADTH; 2019 May. (CADTH rapid response report: summary of abstracts).

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.



Research Questions

 What is the comparative clinical effectiveness of oral glucose tablets versus oral glucose gel or solution for the treatment of mild hypoglycemia in patients of any age?

Key Findings

One systematic review was identified regarding oral glucose tablets versus gel or solution for the treatment of mild hypoglycemia. In addition, one evidence-based guideline was identified.

Methods

A limited literature search was conducted on key resources including PubMed, the Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2014 and April 24, 2019. Internet links were provided, where available.

Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

Population	People of any age experiencing mild hypoglycemia
Intervention	Oral glucose tablets
Comparator	Oral glucose gel; Oral glucose solution
Outcomes	Clinical effectiveness in terms of time to return blood glucose levels to normal range, safety
Study Designs	Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized trials, evidence-based guidelines

Results

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, and evidence-based guidelines.

One systematic review was identified regarding oral glucose tablets versus gel or solution for the treatment of mild hypoglycemia. In addition, one evidence-based guideline was identified. No health technology assessment reports, meta-analyses, randomized controlled trials, or non-randomized trials were identified.

Additional references of potential interest are provided in the appendix.



Overall Summary of Findings

One systematic review was identified regarding oral glucose tablets versus gel or solution for the treatment of mild hypoglycemia.¹ The systematic review by De Buck *et al.* included 77 patients from four studies, of which two studies were randomized controlled trials (RCTs) and two were non-randomized studies.¹ The authors reported low confidence in the body of evidence.¹ Oral glucose was reported to result in a higher blood glucose concentration 20 minutes after administration when compared to buccal glucose administration.¹ There was no significant differences demonstrated between oral glucose tablets, oral glucose solutions or dextrose gel (a product combining buccal and oral routes).¹

The 2018 Diabetes Canada guideline on hypoglycemia recommended patients with diabetes to carry a source of fast-acting carbohydrate at all times such as glucose tablets, juice box, packets of table sugar, etc.² The authors suggested that for people taking acarbose experiencing hypoglycemia, glucose tablets must be used, or milk or honey must be used if glucose tablets are unavailable.²



References Summarized

Health Technology Assessments

No literature identified.

Systematic Reviews and Meta-analyses

 De Buck E, Borra V, Carlson JN, Zideman DA, Singletary EM, Djarv T. First aid glucose administration routes for symptomatic hypoglycaemia. *Cochrane Database Syst Rev.* 2019 Apr 11;4:Cd013283.

PubMed: PM30973639

Randomized Controlled Trials

No literature identified.

Non-Randomized Studies

No literature identified.

Guidelines and Recommendations

Patients with Diabetes

 Yale J-F, Paty B, Senior PA. Hypoglycemia. 2018 Clinical practice guidelines. Can J Diabetes. 2018;42(Sup.1):S104-S108. https://guidelines.diabetes.ca/docs/cpg/Ch14-Hypoglycemia.pdf Accessed 2018 May 3.

See pages S105-S106: Treatment of Hypoglycemia and S106: Recommendations #5



Appendix — Further Information

Previous CADTH Reports

Oral glucose gel for neonatal hypoglycemia: a review of clinical effectiveness, costeffectiveness and guidelines. (CADTH rapid response report: summary with critical
appraisal). Ottawa (ON): CADTH:
https://www.cadth.ca/sites/default/files/pdf/htis/2018/RC0998%20Oral%20Glucose%20Gel%20for%20Neonatal%20Hypoglycemia%20Final.pdf Accessed 2018 May 2.

Systematic Reviews and Meta-analyses – Alternative Interventions

 Carlson JN, Schunder-Tatzber S, Neilson CJ, Hood N. Dietary sugars versus glucose tablets for first-aid treatment of symptomatic hypoglycaemia in awake patients with diabetes: a systematic review and meta-analysis. *Emerg Med J.* 2017 Feb;34(2):100-106.

PubMed: PM27644757

Additional References

- 4. HealthLink BC. Treating low blood sugar. 2017; https://www.healthlinkbc.ca/health-topics/aa20606. Accessed 2019 May 2.
- Diabetes Australia. Hypoglycaemia. 2015 https://www.diabetesaustralia.com.au/hypoglycaemia Accessed 2019 May 2.
- National Institute of Diabetes and Digestive and Kidney Diseases. Low blood glucose (hypoglycemia). 2016; https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia.
 Accessed 2019 May 2.
- Dagens Diabetes. Glucose tablets likely better for easing hypoglycemia symptoms.
 Emergency Medicine Journal. 2016; https://dagensdiabetes.info/index.php/alla-senaste-nyheter/2336-glucose-tablets-likely-better-for-easing-hypoglycemia-symptoms-emergency-medicine-journal. Accessed 2019 May 2.